Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Significant Growth in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 14,600 shares, a growth of 124.6% from the October 31st total of 6,500 shares. Based on an average trading volume of 127,600 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company’s stock are short sold.

Estrella Immunopharma Price Performance

ESLA traded up $0.10 during trading hours on Friday, reaching $1.14. 49,847 shares of the stock traded hands, compared to its average volume of 75,737. Estrella Immunopharma has a fifty-two week low of $0.63 and a fifty-two week high of $3.23. The company has a market cap of $41.06 million, a price-to-earnings ratio of -4.37 and a beta of 0.24. The firm’s fifty day simple moving average is $0.92 and its two-hundred day simple moving average is $1.09.

Estrella Immunopharma (NASDAQ:ESLA) last announced its earnings results on Friday, September 27th. The company reported ($0.13) earnings per share (EPS) for the quarter.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.